Unlock stock picks and a broker-level newsfeed that powers Wall Street.

BSE - Delayed Quote INR

Concord Drugs Limited (CONCORD.BO)

Compare
31.33
+0.36
+(1.16%)
At close: 3:27:29 PM GMT+5:30
Loading Chart for CONCORD.BO
  • Previous Close 30.97
  • Open 30.53
  • Bid 31.40 x --
  • Ask 31.60 x --
  • Day's Range 30.53 - 31.88
  • 52 Week Range 26.10 - 41.00
  • Volume 14,600
  • Avg. Volume 8,332
  • Market Cap (intraday) 313.3M
  • Beta (5Y Monthly) 0.38
  • PE Ratio (TTM) --
  • EPS (TTM) -0.04
  • Earnings Date --
  • Forward Dividend & Yield --
  • Ex-Dividend Date --
  • 1y Target Est --

Concord Drugs Limited engages in the manufacture and sale of pharmaceutical formulations in India. It offers tissue bio-adhesive products. The company also provides ready-to-fill pellets and multiple unit pellets system; drugs in the form of tablets, capsules, small volume parenterals, dry powders, syrups and suspension, and dry syrups; and hand sanitizers. Concord Drugs Limited was incorporated in 1995 and is based in Hyderabad, India.

concorddrugs.in

185

Full Time Employees

March 31

Fiscal Year Ends

Recent News: CONCORD.BO

View More

Performance Overview: CONCORD.BO

Trailing total returns as of 4/16/2025, which may include dividends or other distributions. Benchmark is S&P BSE SENSEX (^BSESN) .

YTD Return

CONCORD.BO
16.90%
S&P BSE SENSEX (^BSESN)
1.40%

1-Year Return

CONCORD.BO
13.74%
S&P BSE SENSEX (^BSESN)
5.62%

3-Year Return

CONCORD.BO
13.74%
S&P BSE SENSEX (^BSESN)
32.06%

5-Year Return

CONCORD.BO
13.74%
S&P BSE SENSEX (^BSESN)
151.76%

Compare To: CONCORD.BO

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Statistics: CONCORD.BO

View More

Valuation Measures

Annual
As of 4/15/2025
  • Market Cap

    309.70M

  • Enterprise Value

    497.66M

  • Trailing P/E

    --

  • Forward P/E

    --

  • PEG Ratio (5yr expected)

    --

  • Price/Sales (ttm)

    0.61

  • Price/Book (mrq)

    0.91

  • Enterprise Value/Revenue

    0.99

  • Enterprise Value/EBITDA

    14.41

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    -0.08%

  • Return on Assets (ttm)

    --

  • Return on Equity (ttm)

    --

  • Revenue (ttm)

    504.95M

  • Net Income Avi to Common (ttm)

    -416k

  • Diluted EPS (ttm)

    -0.04

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    535k

  • Total Debt/Equity (mrq)

    56.35%

  • Levered Free Cash Flow (ttm)

    --

Research Analysis: CONCORD.BO

View More

Company Insights: CONCORD.BO

Research Reports: CONCORD.BO

View More

People Also Watch